Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin and Docetaxel in Recurrent Ovarian Cancer
NCT00504257Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2007
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Moffitt Cancer Center. Primary endpoint: Progression Free Survival at 6 months. Started Mar 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00504257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504257.